5 drug(s) with this reaction
1,186 total reports
Deep Vein Thrombosis has been reported as an adverse reaction across 5 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,186 adverse event reports mention deep vein thrombosis in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with deep vein thrombosis, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have deep vein thrombosis listed in their FDA adverse event reports, sorted by report count:
In addition to deep vein thrombosis, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
5 drug(s) manufactured by Amgen Inc have deep vein thrombosis listed in their FDA adverse event reports: FILGRASTIM, DARBEPOETIN ALFA, ROMIPLOSTIM, PANITUMUMAB, EPOETIN ALFA.
There are a combined 1,186 reports of deep vein thrombosis across 5 Amgen Inc drug(s) in the FDA adverse event database.